AstraZeneca PLC (NASDAQ:AZN) is grappling with an expected earnings decline of 11.58% year-over-year, projecting earnings of $0.84 per share, although its stock recently gained 4.35% to close at $65.98. Despite having a PEG ratio of 1.21 and a forward P/E ratio of 18.28, the company is not among the 30 most popular stocks among hedge funds, despite being held by 42 portfolios. Investor sentiment remains cautiously optimistic due to promising phase 3 data for its treatments, positioning AstraZeneca as a compelling investment opportunity in a challenging financial landscape.
“AstraZeneca · is · a drugmaker · true”
“AstraZeneca · has · a diversified portfolio · over three-dozen products across six major segments”
“AstraZeneca PLC (NASDAQ:AZN) · is · a biopharmaceutical company · biopharmaceutical company”
“AstraZeneca PLC (NASDAQ:AZN) stock · closed at · $65.98 per share · $65.98 per share”
“AstraZeneca PLC (NASDAQ:AZN) · had a one-month return of · -4.34% · -4.34%”
“AstraZeneca PLC (NASDAQ:AZN) · gained · 4.35% · 4.35%”
“AstraZeneca PLC (NASDAQ:AZN) · has a market capitalization of · $205.901 billion · $205.901 billion”
“Artisan Global Equity Fund · bought a stake in · AstraZeneca PLC (NASDAQ:AZN) · AstraZeneca PLC (NASDAQ:AZN)”
“AstraZeneca PLC (NASDAQ:AZN) · presented · phase 3 data for Capivasertib · phase 3 data for Capivasertib”
“AstraZeneca PLC (NASDAQ:AZN) · is not on our list of · 30 Most Popular Stocks Among Hedge Funds · 30 Most Popular Stocks Among Hedge Funds”
“42 hedge fund portfolios · held · AstraZeneca PLC (NASDAQ:AZN) at the end of the fourth quarter · 42 hedge fund portfolios”
“Astrazeneca · closed · trading day · $65.61”
